Phio Pharmaceuticals Announces Presentation at the 9th Annual CAR-TCR Summit in Boston, MA

Sep 16, 2024 | Press Releases

Phio’s INTASYL self-delivering RNAi technology enhances cell potency and yield in Adoptive Cell Therapy Marlborough, Massachusetts–(Newsfile Corp. – September 16, 2024) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology...

Phio Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Sep 9, 2024 | Press Releases

Conference to be held in New York City September 9-11thMarlborough, Massachusetts–(Newsfile Corp. – September 9, 2024) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary INTASYL® siRNA gene...

Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series

Aug 29, 2024 | Press Releases

Presentation and live Q&A to take place Thursday, September 5, 2024, at 12 PM EDTMarlborough, Massachusetts–(Newsfile Corp. – August 29, 2024) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary...

Phio Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update

Aug 14, 2024 | Press Releases

Marlborough, Massachusetts–(Newsfile Corp. – August 14, 2024) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is designed to make immune cells more...

Phio Pharmaceuticals Announces Exploratory Collaboration with a Luxury Skin Care Company for Phio’s Patented INTASYL Compound

Aug 6, 2024 | Press Releases

Phio’s INTASYL compound targets aging skin disordersMarlborough, Massachusetts–(Newsfile Corp. – August 6, 2024) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene...

Phio Pharmaceuticals Announces New Chief Financial Officer

Aug 1, 2024 | Press Releases

Marlborough, Massachusetts–(Newsfile Corp. – August 1, 2024) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is designed to make immune cells more...